Volume 21, Issue 4 (8-2018)
J Arak Uni Med Sci 2018, 21(4): 40-47 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
talaei A, Mahmoudpoor M, shahdost M. The Effect of Atorvastatin on Inflammatory Markers in Patients with Type Two Diabetes . J Arak Uni Med Sci 2018; 21 (4) :40-47
URL: http://jams.arakmu.ac.ir/article-1-5788-en.html
URL: http://jams.arakmu.ac.ir/article-1-5788-en.html
1- Department of Endocrinology, Arak University of Medical Sciences, Arak, Iran. , afsanehtalaeii@yahoo.com
2- Department of Nephrology, Bushehr University of Medical Sciences, Bushehr, Iran.
3- Department of Statistic, Arak University of Medical Sciences, Arak, Iran.
2- Department of Nephrology, Bushehr University of Medical Sciences, Bushehr, Iran.
3- Department of Statistic, Arak University of Medical Sciences, Arak, Iran.
Abstract: (3415 Views)
Background and Aim: Regarding to paradoxical results of the studies about the effects of atorvastatin on inflammatory markers and metabolism, we aimed to evaluate the effects of atorvastatin on inflammatory markers in diabetic patients.
Materials and Methods: Through a double blind randomized clinical trial, placebo control, 88 type two diabetic patients (T2DP), were treated with anti-diabetes oral agents, were randomly classified into two 44 cases groups. The intervention group took atorvastatin 40 mg daily and control group took placebo for three months and adiponectin, hsCRP, leptin, TNF-α, lipid profile and fasting blood glucose (FBS) were measured and compared at the beginning and the end of the study. The data were analyzed using student t test and paired t test.
Findings: After three months, adiponectin was significantly increased in intervention group in comparison to control group, but leptin had not a significant change in two groups. Total cholesterol, hsCRP and LDL cholesterol (Low density Lipoprotein) were decreased significantly in the intervention group than control group, while FBS was
non-significantly decreased.
Conclusion: It seems atorvastatin is effective to decrease inflammatopry markers in diabetic patients.
Materials and Methods: Through a double blind randomized clinical trial, placebo control, 88 type two diabetic patients (T2DP), were treated with anti-diabetes oral agents, were randomly classified into two 44 cases groups. The intervention group took atorvastatin 40 mg daily and control group took placebo for three months and adiponectin, hsCRP, leptin, TNF-α, lipid profile and fasting blood glucose (FBS) were measured and compared at the beginning and the end of the study. The data were analyzed using student t test and paired t test.
Findings: After three months, adiponectin was significantly increased in intervention group in comparison to control group, but leptin had not a significant change in two groups. Total cholesterol, hsCRP and LDL cholesterol (Low density Lipoprotein) were decreased significantly in the intervention group than control group, while FBS was
non-significantly decreased.
Conclusion: It seems atorvastatin is effective to decrease inflammatopry markers in diabetic patients.
References
1. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259:87-91.
2. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature. 1997; 389:610-614.
3. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 1996; 271: 665-668.
4. Aguirre V, Uchida T, Yenush L, Davis R, White MF. The c-Jun NH (2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser (307). J Biol Chem. 2000; 275:9047-9054.
5. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends in Endocrinology & Metabolism. 2002; 13(2):84-9.
6. Steppan CM, Lazar MA. The current biology of resistin. J Intern Med. 2004; 255:439-447.
7. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005; 307:426-430.
8. Díez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003; 148 (3): 293–300.
9. Nedvídková J, Smitka K, Kopský V, Hainer V. Adiponectin, an adipocyte-derived protein . Physiol Res 2005; 54 (2): 133–40.
10. Renaldi O, Pramono B, Sinorita H, Purnomo LB, Asdie RH, Asdie AH. Hypoadiponectinemia: a risk factor for metabolic syndrome. Acta Med Indones 2009; 41 (1): 20–4.
11. Shyu KG, Chua SK, Wang BW, Kuan P. Mechanism of inhibitory effect of atorvastatin on resistin expression induced by tumor necrosis factor-alpha in macrophages. J Biomed Sci. 2009; 27(16):50.
12. Sethi JK, Hotamisligil GS. The role of TNF alpha in adipocyte metabolism. Semin. Cell Dev. Biol 1999; 10:19-29.
13. White, MF. The insulin signalling system and the IRS proteins. Diabetologia. 1997; 40(Suppl. 2): S2-S17.
14. Saltiel AR, Pessin JE. Insulin signaling pathways in time and space. Trends Cell Biol. 2002; 12:65-71.
15. Strom A, Kolb H, Martin S, Herder C, Simon MC, Koenig W, et al. Improved preservation of residual beta cell function by atorvastatin in patients with recent onset type 1 diabetes and high CRP levels (DIATOR trial). PLoS One. 2012; 7(3): e33108
16. Martín-Ventura JL, Blanco-Colio LM, Gómez-Hernández A, Muñoz-García B, Vega M, Serrano J, et al. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month. Stroke. 2005; 36(8):1796-800
17. El-Barbary AM, Hussein MS, Rageh EM, Hamouda HE, Wagih AA, Ismail RG. Effect of atorvastatin on inflammation and modification of vascular risk factors in rheumatoid arthritis. J Rheumatol. 2011; 38(2):229-35.
18. Sathyapalan T, Atkin SL, Kilpatrick ES. Disparate effects of atorvastatin compared with simvastatin on C-reactive protein concentrations in patients with type 2 diabetes. Diabetes Care. 2010; 33(9):1948-50.
19. Wägner AM, Sánchez-Quesada JL, Benítez S, Bancells C, Ordóñez-Llanos J, Pérez A. Effect of statin and fibrate treatment on inflammation in type 2 diabetes. A randomized, cross-over study. Diabetes Res Clin Pract. 2011; 93(1): e25-8
20. Thongtang N, Ai M, Otokozawa S, Himbergen TV, Asztalos BF, Nakajima K, et al. Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation. Am J Cardiol. 2011; 107(3):387-92.
21. von Eynatten M, Liu D, Bluemm A, Schuster T, Baumann M, Lutz J, et al. Changes in adiponectin multimer distribution in response to atorvastatin treatment in patients with type 2 diabetes. Clin Endocrinol (Oxf). 2009; 71(1):27-32.
22. Li M, Xu A, Lam KS, Cheung BM, Tse HF. Impact of combination therapy with amlodipine and atorvastatin on plasma adiponectin levels in hypertensive patients with coronary artery disease: combination therapy and adiponectin. Postgrad Med. 2011; 123(6):66-71.
23. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006; 116(7):1784-92.
24. Zhao SP, Wu ZH. Atorvastatin reduces serum leptin concentration in hypercholesterolemic rabbits. Clin Chim Acta. 2005; 360(1-2): 133-40.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
